In 2025, EssilorLuxottica continues to advance its global leadership in myopia management, reaching more children than ever with innovative solutions that help slow the progression of myopia. Through unwavering commitment and collaboration, it is empowering the next generation to see their world more clearly today — and preserve their vision for tomorrow.

Expanding Its Myopia Management Platform
The Group recently expanded its myopia management platform with new Essilor Stellest 2.0 lenses powered by H.A.L.T.* MAX technology that deliver significantly higher efficacy in slowing myopic eye growth.^1,2 The platform also includes Essilor Stellest plano pair lenses for early intervention; designed to help delay the onset of myopia^2,3 and Essilor Stellest Smartglasses, developed to provide behavioral insights and support consistent wearing compliance.⁴In addition, Nikon and Kodak DOT (Diffusion Optics technology) lenses are now worn by more than 1 million children.

Essilor Stellest Lens: The First and Only FDA Market Authorized Spectacle Lens in the US
Marking an important milestone in the industry, Essilor Stellest lenses are now recognized as the first and only FDA market authorized spectacle lens in the United States^5,6 for slowing myopia progression in children. They provide US eyecare professionals with a clinically validated, non-invasive option that can help slow myopia progression in children.

New Clinical Data Reinforces Long-Term Efficacy of Essilor Stellest Lenses
The impactful announcement on FDA market-authorization followed the unveiling of new six-year clinical data reinforcing the long-term efficacy of Essilor Stellest lenses in managing myopia progression and axial elongation in children and young adults.⁷ The results underscore the significant and sustained impact of Essilor Stellest lenses in controlling myopia progression, offering valuable insights into strategies for addressing the global myopia epidemic.

Celebrating 45 years of Innovation and Research in Myopia Management
On the occasion of Myopia Awareness Week 2025 in May, EssilorLuxottica celebrated 45 years of research and experience in myopia management, reaffirming its commitment to advancing innovation, education, awareness and access.

Throughout 2025, EssilorLuxottica again guided the global conversation on myopia management at key scientific conferences, including the CCOI Myopia Workshop, ARVO, BCLA, EAOO, the International Myopia Society Meeting, Ophthalmology Futures Forums, WSPOS Subspecialty Day, EURETINA, EVER, and Academy 2025, among others. The Group also actively educated eyecare professionals and promoted awareness through strategic partnerships with Review of Myopia Management, Myopia Profile, WSPOS, Global Myopia Awareness Coalition and the International Myopia Institute.

Looking forward, EssilorLuxottica will continue to tackle the growing global myopia epidemic through pioneering innovation, evidence-based research and cross-sector collaboration that inspires lasting change for vision health worldwide.

_{^{*H.A.L.T., Highly Aspherical Lenslet Target}}
_{^{1.Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 children. EssilorLuxottica data on file (2025).}}
_{^{2. Essilor Stellest 2.0 and Essilor Stellest plano pair (for pre-myopia) are not currently available in the U.S.}}
_{^{3. Zhang Z, Zeng L, Gu D, et al. Spectacle Lenses With Highly Aspherical Lenslets for Slowing Axial Elongation and Refractive Change in Low-Hyperopic Chinese Children: A Randomized Controlled Trial. Am J Ophthalmol 2025; 269: 60–68 Click}}_^here_{^{to view the study.}}
_{^{4. Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, Wang C, Li Y, Lim EW, Spiegel DP, Drobe B, Chen, H. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA ophthalmology. 2022;140(5):472-8. doi:10.1001/jamaophthalmol.2022.0401.}}
_{^{5. Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.}}
_{^{6. Essilor International, data on file (2025)}}
_{^{7. The long-term efficacy of Essilor® Stellest® lenses was evaluated over 6 years in 42 Chinese children aged 8-13 at baseline. Myopia progression outcomes were compared to the 72-month progression of an extrapolated control group based on the initial 2-year control group (Bao et al., JAMA Ophthalmology. 2022; 140(5):472-478). The model predicted 72-month myopia progression using an estimated annual reduction rate in spherical equivalent refraction of 9.7% (Smotherman et al., IOVS. 2023;64(8):811). (Unpublished results. Presented at BCLA 2025).}}